Loading patent…
OwnerAlfredo MARTÍNEZ RAMÍREZ, Alfonso MARTÍN CARNICERO +7inventors
InventorsAlfredo MARTÍNEZ RAMÍREZ, Alfonso MARTÍN CARNICERO, Pilar MARTÍNEZ MORAL, Francisco CORZANA LÓPEZ, Alicia ASÍN VICENTE, Roberto FIAMMENGO, Ander EGUSKIZA BILBAO, Giovanni MALERBA, Elisa DE TOMI
Estimating the term…
The present invention relates to a glycopeptide derived from MUC1 the sequence of which consists of SEQ ID NO 2 (CGGGGPAPGST(GalNCOEt)APPA) for use as a pancreatic cancer biomarker by binding the glycopeptide to tumour-associated anti-MUC1 antibodies, the glycopeptide being attached to a nanoparticle. Likewise, the invention provides a kit for detecting and quantifying anti-MUC1 antibodies in a biological sample isolated from an individual, wherein the kit is configured for detecting and quantifying binding between anti-MUC1 antibodies, present in the sample, and the glycopeptide of the invention by visualising and quantifying fluorescent signals.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Synthetic non-natural glycopeptides, as represented by [GGGGPGPAPGST(GalNCOEt)APPA] and/or [CGGGGPAPGST(GalNCOEt)APPA] and/or their derivative synthetic glycopeptides for use as cancer biomarker detectors in the detection of early stage tumours.
A biomarker binding platform comprising a nanoparticle and a covalently bound synthetic non-natural glycopeptide antigen, as represented by [CGGGGPAPGST(GalNCOEt)APPA] and/or its derivative glycopeptide antigens for use as cancer biomarker detectors in the detection of early stage tumours.
Dependencies are inferred from the claim text.